Australia’s Therapeutic Goods Administration (TGA) has certified Capsugel’s (Greenwood, SC) Licaps liquid-fill production facility meets its regulatory requirements, the company announced on August 7.“The Australian GMP code is very thorough because it covers all medicines and is highly respected by many regulatory authorities around the world,” said Robert Whitelaw, director of sales, marketing, and business development for Capsugel’s Americas region.
Australia’s Therapeutic Goods Administration (TGA) has certified Capsugel’s (Greenwood, SC) Licaps liquid-fill production facility meets its regulatory requirements, the company announced on August 7.
“The Australian GMP code is very thorough because it covers all medicines and is highly respected by many regulatory authorities around the world,” said Robert Whitelaw, director of sales, marketing, and business development for Capsugel’s Americas region.
To obtain the certification, the company demonstrated its compliance with Australian good manufacturing practices for medicinal products, Whitelaw said. The certification should enable marketers to expand into the Australian market and in other regions that recognize TGA certification.
“In conjunction with the growing demand for products that utilize the Licaps delivery system, our customers can now more readily access important global markets,” added Whitelaw. “Certainly, our experience is that the important benefits of the Licaps delivery system, which include heightened consumer preference and improved bioavailability, address global needs.”
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.